hVIVO plc (LON:HVO – Get Free Report)’s stock price was down 6.8% during mid-day trading on Thursday . The stock traded as low as GBX 19 ($0.24) and last traded at GBX 19.10 ($0.24). Approximately 2,518,262 shares traded hands during trading, a decline of 26% from the average daily volume of 3,389,765 shares. The stock had previously closed at GBX 20.50 ($0.25).
hVIVO Price Performance
The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86. The company has a market capitalization of £129.95 million, a P/E ratio of 636.67 and a beta of 0.97. The stock has a 50 day moving average price of GBX 23.20 and a 200 day moving average price of GBX 26.66.
About hVIVO
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Read More
- Five stocks we like better than hVIVO
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
- 3 Fintech Stocks With Good 2021 Prospects
- Nebius Group: The Rising Star in AI Infrastructure
- What Are Some of the Best Large-Cap Stocks to Buy?
- MarketBeat Week in Review – 12/30 – 1/03
Receive News & Ratings for hVIVO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for hVIVO and related companies with MarketBeat.com's FREE daily email newsletter.
